Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Endocrinology
Volume 2013, Article ID 636175, 6 pages
http://dx.doi.org/10.1155/2013/636175
Case Report

A Case of Inoperable Malignant Insulinoma with Resistant Hypoglycemia Who Experienced the Most Significant Clinical Improvement with Everolimus

1Division of Endocrinology and Metabolism, Adana Medical Center, Baskent University School of Medicine, Dadaloglu Mah. Serin Evler 39, Sok. No. 6 Yuregir, 01250 Adana, Turkey
2Division of Medical Oncology, Adana Medical Center, Baskent University School of Medicine, Dadaloglu Mah. Serin Evler 39, Sok. No. 6 Yuregir, 01250 Adana, Turkey
3Division of Radiology, Adana Medical Center, Baskent University School of Medicine, Dadaloglu Mah. Serin Evler 39, Sok. No. 6 Yuregir, 01250 Adana, Turkey
4Division of Nuclear Medicine, Adana Medical Center, Baskent University School of Medicine, Dadaloglu Mah. Serin Evler 39, Sok. No. 6 Yuregir, 01250 Adana, Turkey
5Division of Pathology, Adana Medical Center, Baskent University School of Medicine, Dadaloglu Mah. Serin Evler 39, Sok. No. 6 Yuregir, 01250 Adana, Turkey

Received 10 March 2013; Accepted 12 April 2013

Academic Editors: M. Demura, O. Isozaki, and T. Usui

Copyright © 2013 Emre Bozkirli et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. W. W. de Herder, “Insulinoma,” Neuroendocrinology, vol. 80, no. 1, pp. 20–22, 2004. View at Publisher · View at Google Scholar · View at Scopus
  2. A. Mathur, P. Gorden, and S. K. Libutti, “Insulinoma,” Surgical Clinics of North America, vol. 89, no. 5, pp. 1105–1121, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. K. Oberg, “Pancreatic endocrine tumor,” Seminars in Oncology, vol. 37, pp. 594–618, 2010. View at Google Scholar
  4. C. Grant and K. Vanderveen, “Insulinoma,” Cancer Treatment and Research, vol. 153, pp. 235–252, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. F. T. Bosman, F. Carneiro, R. H. Hruban, and N. D. Theise, WHO Classification of Tumours of the Digestive System, International Agency for Research on Cancer, (IARC), Lyon, France, 4th edition, 2010.
  6. R. R. Perry and A. I. Vinik, “Diagnosis and management of functioning islet cell tumors,” The Journal of Clinical Endocrinology & Metabolism, vol. 80, no. 8, pp. 2273–2278, 1995. View at Google Scholar · View at Scopus
  7. D. N. Danforth, P. Gorden, and M. F. Brennan, “Metastatic insulin-secreting carcinoma of the pancreas: clinical course and the role of surgery,” Surgery, vol. 96, no. 6, pp. 1027–1036, 1984. View at Google Scholar · View at Scopus
  8. G. V. Gill, O. Rauf, and I. A. MacFarlane, “Diazoxide treatment for insulinoma: a national UK survey,” Postgraduate Medical Journal, vol. 73, no. 864, pp. 640–641, 1997. View at Google Scholar · View at Scopus
  9. W. W. De Herder, E. van Schaik, D. Kwekkeboom, and R. A. Feelders, “New therapeutic options for metastatic malignant insulinomas,” Clinical Endocrinology, vol. 75, no. 3, pp. 277–284, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. A. J. Krentz, P. J. Boyle, L. M. Macdonald, and D. S. Schade, “Octreotide: a long-acting inhibitor of endogenous hormone secretion for human metabolic investigations,” Metabolism, vol. 43, no. 1, pp. 24–31, 1994. View at Publisher · View at Google Scholar · View at Scopus
  11. P. Chandra, S. S. Yarandi, N. Khazai, S. Jacobs, and G. E. Umpierrez, “Management of intractable hypoglycemia with Yttirum-90 radioembolization in a patient with malignant insulinoma,” American Journal of the Medical Sciences, vol. 340, no. 5, pp. 414–417, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. J. C. Maiza, D. Vezzosi, S. Grunenwald et al., “Treatment with somatostatin analogs and chemoembolization of liver metastases for severe hypoglycemia in malignant insulinomas,” Journal of Endocrinological Investigation, vol. 34, no. 9, pp. 253–258, 2011. View at Google Scholar
  13. E. van Schaik, E. I. van Vliet, R. A. Feelders et al., “Improved control of severe hypoglycemia in patients with malignant insulinomas by peptide receptor radionuclide therapy,” The Journal of Clinical Endocrinology & Metabolism, vol. 96, no. 11, pp. 3381–3389, 2011. View at Google Scholar
  14. D. K. Fuhrer, M. Kobayashi, and H. Jiang, “Insulin release and suppression by tacrolimus, rapamycin and cyclosporin A are through regulation of the ATP-sensitive potassium channel,” Diabetes, Obesity and Metabolism, vol. 3, no. 6, pp. 393–402, 2001. View at Publisher · View at Google Scholar · View at Scopus
  15. J. C. Yao, M. H. Shah, T. Ito et al., “Everolimus for advanced pancreatic neuroendocrine tumors,” The New England Journal of Medicine, vol. 364, no. 6, pp. 514–523, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. M. H. Kulke, E. K. Bergsland, and J. C. Yao, “Glycemic control in patients with insulinoma treated with everolimus,” The New England Journal of Medicine, vol. 360, no. 2, pp. 195–197, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. N. Thomas, A. Brooke, and G. Besser, “Long-term maintenance of normoglycaemia using everolimus in a patient with disseminated insulinoma and severe hypoglycaemia,” Clinical Endocrinology, vol. 78, no. 5, pp. 799–800, 2012. View at Publisher · View at Google Scholar
  18. H. B. Fiebrich, E. J. M. Siemerink, A. H. Brouwers et al., “Everolimus induces rapid plasma glucose normalization in insulinoma patients by effects on tumor as well as normal tissues,” Oncologist, vol. 16, no. 6, pp. 783–787, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. C. D. A. Stehouwer, W. F. Lems, H. R. A. Fischer, W. H. L. Hackeng, and M. A. B. Naafs, “Aggravation of hypoglycemia in insulinoma patients by the long-acting somatostatin analogue octreotide (Sandostatin),” Acta Endocrinologica, vol. 121, no. 1, pp. 34–40, 1989. View at Google Scholar · View at Scopus
  20. D. Vezzosi, A. Bennet, P. Rochaix et al., “Octreotide in insulinoma patients: efficacy on hypoglycemia, relationships with Octreoscan scintigraphy and immunostaining with anti-sst2A and anti-sst5 antibodies,” European Journal of Endocrinology, vol. 152, no. 5, pp. 757–767, 2005. View at Publisher · View at Google Scholar · View at Scopus
  21. A. S. Kennedy, W. A. Dezarn, P. McNeillie et al., “Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients,” American Journal of Clinical Oncology, vol. 31, no. 3, pp. 271–279, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. H. J. Mauceri, H. G. Sutton, T. E. Darga et al., “Everolimus exhibits efficacy as a radiosensitizer in amodel of non-small cell lung cancer,” Oncology Reports, vol. 27, no. 5, pp. 1625–1629, 2012. View at Google Scholar